Home
Home
  • Home
  • About Us About Us
    • Overview
    • Who we are
    • Why we provide advice
    • What are health technologies
    • Meetings
    • News
    • Who we work with
    • Contact Us
  • What We Do What We Do
    • Overview
    • Our Strategy
    • Work programme
    • Range of advice products
    • Quarterly Bulletin of advice
    • Early HTA Advice Service
  • Our Advice
  • Request Advice Request Advice
    • Overview
    • Form for requesting advice
  • Get Involved Get Involved
    • Overview
    • Contribute to advice
    • NHS boards
    • Patient and Public Involvement
    • Industry Involvement
    • Observe a council meeting
    • DOI Form

Advice Statement

  • Home
  • Our Advice
  • Carbapenemase-producing Enterobacteriaceae (CPE) in hospital screening samples obtained from patients identified as at risk of CPE colonisation

Title

Output Type

Speciality

Published

Title

Carbapenemase-producing Enterobacteriaceae (CPE) in hospital screening samples obtained from patients identified as at risk of CPE colonisation

Output Type

Advice Statement

Speciality

Infectious disease

Published

2 December 2016

Recommendation for NHSScotland

The literature on identifying carbapenemase producing Enterobacteriaceae in hospital screening samples is inadequate to inform selection of tests. Considerations around screening test selection should include:

  • The prevalence of each carbapenemase in the at-risk population
  • Individual clinical microbiology laboratory and overall service capabilities
  • The ability to identify high risk patient groups and
  • Availability of and costs associated with isolation beds.

Selection of the most appropriate test(s) for NHSScotland will require consensus around the balance between overall costs and turnaround times alongside an understanding of the strengths and limitations of each testing strategy in terms of the accuracy and utility of the information each provides both within a routine screening context and in an outbreak situation.

NHSScotland is required to consider the Scottish Health Technologies Group (SHTG) advice.

What were we asked to look at?

What is the published evidence on the accuracy, turnaround time and cost/costeffectiveness of tests to identify carbapenemase producing Enterobacteriaceae (CPE) in hospital screening samples obtained from patients identified as at risk of CPE colonisation during clinical risk assessment?

Why is this important?

The rapid emergence and spread of Enterobactericeae resistant to carbapenems is a critical clinical and public health issue.

In August 2013 a letter from the Chief Medical Officer, Chief Nursing Officer and Chief Pharmaceutical Officer to NHS Boards in Scotland set out the threat posed by this issue, the increasing instances of CPE detection in Scotland and the principles for combating the threat. In addition to early detection and prudent antibiotic prescribing, the requirement for the implementation of screening and infection control measures was detailed.

A rectal swab is considered the best sample type for screening in this context. To date the use of screening to identify asymptomatic carriers is variable across Scotland with many NHS boards screening only on an ad hoc basis. 

Referred by

Health Protection Scotland

Download icon
Download Advice
pdf (348 KB)
Download icon
Download Evidence Note
pdf (2 MB)

Connect with Us

Please let us know if you'd like to receive regular updates on our work.


Last Updated: 5 August 2021

Scottish Health Technologies Group

© 2021, All rights reserved

  • Accessibility
  • Respecting your privacy
  • Cookies
  • Healthcare Improvement Scotland Website
  • Find us on Twitter
  • Freedom of Information

Tell us what you think


We'd love to hear your views

Was our advice useful?  Did you find what you were looking for on our website?